Prophylactic LMWH vs placebo
Adverse effects of treatment · people with ST of the leg
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Findings
What do systematic reviews say?
9 questions · 9 findings · 2 reviews · Vascular
No studies found 4 · 44.4%GRADE not reported 0 · 0%Very low 2 · 22.2%Low 2 · 22.2%Moderate 1 · 11.1%High 0 · 0%
Therapeutic LMWH vs placebo
Adverse effects of treatment · people with ST of the leg
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
NSAIDs vs placebo
Adverse effects of treatment · people with superficial thrombophlebitis of the leg
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Fondaparinux vs placebo
Adverse effects of treatment · people with ST of the leg
Fondaparinux showed no clear difference in adverse effects of treatment compared with placebo (moderate certainty).
1 finding from 1 review
- RR 1.13 [0.78, 1.65]1 study · 2987 participantsModerate
TNF‐α blockers intervention vs placebo or additional treatment
Adverse effects after treatment initiation: infections · children diagnosed with Kawasaki disease
TNF‐α blockers intervention showed no clear difference in adverse effects after treatment initiation: infections compared with placebo or additional treatment (low certainty).
1 finding from 1 review
- TNF‐α blockers for the treatment of Kawasaki disease in children 2019 · Cochrane Headline outcomes onlyRR 0.68 [0.33, 1.37]2 studies · 227 participantsLow
TNF‐α blockers intervention vs placebo or additional treatment
Infusion reactions · children diagnosed with Kawasaki disease
TNF‐α blockers intervention may leads to lower adverse effects after treatment initiation: infusion reactions compared with placebo or additional treatment (low certainty).
1 finding from 1 review
- TNF‐α blockers for the treatment of Kawasaki disease in children 2019 · Cochrane Headline outcomes onlyRR 0.06 [0.01, 0.45]3 studies · 250 participantsLow
TNF‐α blockers intervention vs placebo or additional treatment
Rash · children diagnosed with Kawasaki disease
It is very uncertain whether TNF‐α blockers intervention changes adverse effects after treatment initiation: cutaneous reactions (rash) compared with placebo or additional treatment (very low certainty).
1 finding from 1 review
- TNF‐α blockers for the treatment of Kawasaki disease in children 2019 · Cochrane Headline outcomes onlyRR 4.71 [0.24, 90.69]1 study · 31 participantsVery low
TNF‐α blockers intervention vs placebo or additional treatment
Adverse effects: contact dermatitis · children diagnosed with Kawasaki disease
It is very uncertain whether TNF‐α blockers intervention changes adverse effects after treatment initiation: cutaneous reactions… compared with placebo or additional treatment (very low certainty).
1 finding from 1 review
- TNF‐α blockers for the treatment of Kawasaki disease in children 2019 · Cochrane Headline outcomes onlyRR 0.31 [0.04, 2.68]1 study · 31 participantsVery low
TNF‐α blockers intervention vs placebo or additional treatment
Adverse effects after treatment initiation: injection site reactions, neutropenia, infections, demyelinating disease, heart failure, malignancy, and induction of autoimmunity. · children diagnosed with Kawasaki disease
The review found no eligible studies for this question.
1 finding from 1 review
- TNF‐α blockers for the treatment of Kawasaki disease in children 2019 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found